Home »
QUICK LINKS

Share this page with
a friend or colleague

Global Forum

Also available in: Français Español

Join us online at #MSKCongress

Global Forum
gf@wfh.org

Mark your calendars! The 13th World Federation of Hemophilia (WFH) Global Forum will take place in-person from November 17 to 18, 2023, at the Fairmont Queen Elizabeth hotel in beautiful Montreal, Canada. This year’s forum will focus on the latest advances in treatments and technologies for bleeding disorders.

The WFH Global Forum is an essential event for anyone with an interest in the developments that are shaping the global bleeding disorders community today. With several new therapeutic options in the pipeline, it’s time to collectively assess these advances, identify their strengths and limitations, determine what will facilitate or hinder their adoption, and evaluate their impact on patients. The forum will cover many of these topics and more, including the following:

  • Confronting limitations of therapies, from plasma to gene therapy
  • Therapeutic options for people with moderate/mild hemophilia patients, women and girls with bleeding disorders, and rare bleeding disorders
  • Inequities in healthcare delivery
  • Innovative access programs
  • Hot topics

This year’s event features an updated format that will feature a discussion specific to gene therapy. By integrating gene therapy into the WFH Global Forum, attendees will have the chance to hear from the leading experts in the field and participate in the ongoing discussions of what is impacting care in our field today.

The Global Forum will be co-chaired by Glenn Pierce, MD, PhD, WFH Vice President Medical, and Mike Makris, MD.

We look forward to welcoming you in Montreal this November!

GOVERNMENTAL WELCOME

The Right Honourable Justin Trudeau, Prime Minister of Canada and François Legault, the Premier of Quebec both extend a warm welcome to all attending the 13th WFH Global Forum in Montreal this year.

Read the letter from Justin Trudeau, Prime Minister of Canada.

Read the letter from François Legault, Premier of Quebec.

Read the letter from Justin Trudeau, Prime Minister of Canada.

 

Read the letter from François Legault, Premier of Quebec.

 

AGENDA

Note: the 13th WFH Global Forum is only offered in English.

Calendar

8:15-8:30

OPENING: Welcome

 
 

Glenn Pierce, Vice-President – Medical, World Federation of Hemophilia, La Jolla, United States
Mike Makris, Professor, University of Sheffield, Sheffield, United Kingdom


8:30-10:35

SESSION 1: Confronting limitations of therapies

 
 

The first 2 sessions of the 13th WFH Global Forum will focus on confronting limitations of therapies for all people with bleeding disorders. Speakers in this session will discuss issues related to plasma, orphan inherited bleeding disorders, treatment of moderate & mild patients, women & girls with bleeding disorders, as well as platelet disorders. The second session will focus on the treatment of hemophilia A and B.

Chair
Glenn Pierce, Vice-President – Medical, World Federation of Hemophilia, La Jolla, United States

Welcome and introductions
Glenn Pierce, Vice-President – Medical, World Federation of Hemophilia, La Jolla, United States

Classification of severity of hemophilia: Do we need a change?
Mike Makris, Professor, University of Sheffield, Sheffield, United Kingdom
Johnny Mahlangu, Professor, University of the Witwatersrand and NHLS, Johannesburg, South Africa

Plasma supply & demand
Brian O’Mahony, CEO, Irish Haemophilia Society, Dublin, Ireland

Orphan inherited bleeding disorders
Magdalena Lewandowska, Adult Hematologist-Oncologist, Indiana Hemophilia and Thrombosis Center (IHTC), Indianapolis, United States

Treatment of moderate and mild patients
Samantha Gouw, Pediatric Hematologist, Amsterdam UMC, Amsterdam, Netherlands

Optimal therapies for women & girls with bleeding disorders
Dawn Rotellini, Chief Operating Officer, National Bleeding Disorders Foundation, Gibsonia, United States

Platelet transfusions & substitutes
Catherine Hayward, Professor, Pathology & Molecular Medicine, McMaster University, Hamilton, Canada


10:35-11:00

BREAK


11:00-12:25

SESSION 2: Confronting limitations of therapies

 
 

The first 2 sessions of the 13th WFH Global Forum will focus on confronting limitations of therapies for all people with bleeding disorders. Speakers in this session will focus on the treatment of hemophilia, discussing CFCs, factor VIII mimetics, rebalancing agents, and gene therapy. Issues specific to gene therapy will also be addressed. This will build upon the previous session which will focus on plasma, other bleeding disorders, moderate & gild patients, and women and girls with bleeding disorders.

Chair
Mike Makris, Professor, University of Sheffield, Sheffield, United Kingdom

Welcome and Introductions
Mike Makris, Professor, University of Sheffield, Sheffield, United Kingdom

Limitations of therapies: Hemophilia A (CFCs, GT, factor VIII mimetics)
Margareth Ozelo, Professor, Hemocentro Unicamp, Sao Paulo, Brazil

Limitations of therapies: Hemophilia B (CFCs, GT)
Steven Pipe, Professor of Pediatrics and Pathology, University of Michigan, Ann Arbor, United States

Limitations of therapies: Hemophilia A & B (rebalancing agents)
Pratima Chowdary, Consultant Haematologist, Royal Free Hospital, London, United Kingdom

Real world implications of antibodies & assay issues in gene therapy
Radoslaw Kaczmarek, Assistant Research Professor of Pediatrics, Indiana University School of Medicine, Indiana, United States


12:25-13:25

LUNCH


13:25-14:50

SESSION 3: Inequities in health care delivery

The afternoon of day 1 will focus on inequities in health care delivery and innovative access programs. Following a presentation on the affordability of global bleeding disorders treatment, new therapeutic approaches to optimize treatment in countries with limited resources will be presented. The following session will address issues related to the establishment of gene therapy programs in lower income countries as well as corporate partner innovative access programs.

Chair
David Lillicrap, Professor, Queen’s University, Kingston, Canada

Welcome and introductions
David Lillicrap, Professor, Queen’s University, Kingston, Canada

Affordability of global bleeding disorders treatment
Brian O’Mahony, CEO, Irish Haemophilia Society, Dublin, Ireland

Emicizumab: Low dose or non-standard interval doses
Alfonso Iorio, Professor, Mcmaster University, Hamilton, Canada

Use of bispecific antibodies in low-income countries: Lessons from the humanitarian aid program
Cedric Hermans, Hematologist, Cliniques universitaires Saint-Luc, Brussels, Belgium

Using BT200 (rondaptivon pegol) in countries with limited access to CFCs
James Gilbert, Lexington, United States
Andrea Edginton, Professor and Hallman Director, School of Pharmacy, University of Waterloo, Waterloo, Canada


14:50-15:20

BREAK


15:20-17:05

SESSION 4: Inequities in health care delivery / Innovative access programs

The afternoon of day 1 will focus on inequities in health care delivery and innovative access programs. Speakers in this session will present achievements and challenges of establishing gene therapy trials in different lower income country settings, as well as different corporate partner innovative access programs. This will build upon the previous session which will address affordability and new therapeutic approaches to optimize treatment in countries with limited resources.

Chair
Cedric Hermans, Hematologist, Cliniques universitaires Saint-Luc, Brussels, Belgium

Welcome and introductions
Cedric Hermans, Hematologist, Cliniques universitaires Saint-Luc, Brussels, Belgium

St. Judes – Achievements and challenges in establishing a gene therapy trial in low-income countries
Ulrike Reiss, Associate Member, St. Jude Children’s Research Hospital, Memphis, United States

Achievements and challenges in establishing a gene therapy trial in low-income countries
Alok Srivastava, Professor, Christian Medical College, Vellore, Indiaf

Sanofi – Global Health Access programs
Cecile Le Camus, Global Head of Medical Affairs Rare Diseases, Sanofi Genzyme

Pfizer – ACCORD program
Lisa Wilcox, Global Medical Lead – Hemophilia, Pfizer, Ajax, Canada

Roche – Innovative access strategies for emicizumab
Martynas Aizenas, Global Access Strategy Leader, Roche, Basel, Switzerland


19:00-21:00

RECEPTION

All times are listed in eastern time (ET)

Program is subject to change









By invitation only
Simultaneous interpretation available in Spanish, French, Russian & Arabic
Program is subject to change

COMMITTEE & SPEAKERS

Show all

Committee

Speakers

Alfonso Iorio

Professor, McMaster University
Hamilton, Canada

Alok Srivastava

Professor, Christian Medical College
India

André Picard

Health columnist, The Globe and Mail
Vancouver, Canada

Andrea Edginton

Professor and Hallman Director, University of Waterloo
Waterloo, Canada

Assad Haffar

Medical & Humanitarian Aid Director, WFH
Montreal, Canada

Brian O'Mahony

CEO, Irish Haemophilia Society
Dublin, Ireland

Catherine Hayward

Professor, Pathology & Molecular Medicine, McMaster University
Hamilton, Canada

Cecile Le Camus

Global Head of Hemophilia with Medical Affairs Rare Blood Disorders, Sanofi
Cambridge, United States

Cedric Hermans

Head, Hemophilia Center Cliniques Universitaires Saint-Luc
Brussels, Belgium

David Lillicrap

Professor, Queen's University
Kingston, Canada

David Rind

Chief Medical Officer, ICER
Boston, United States

Davide Matino

Assistant Professor
Thrombosis and Atherosclerosis Research Institute (TaARI) - McMaster University
Hamilton, Canada

Dawn Rotellini

Chief Operating Officer, National Bleeding Disorders Foundation
Gibsonia, United States

Donna Coffin

Director, Research & Education, WFH
Montreal, Canada

Flora Peyvandi

President, ISTH
Milan, Italy

Glenn Pierce

Vice-President, Medical, WFH
United States

James Gilbert

Lexington, United States

Johannes Oldenburg

Director, Institute for Experimental Haematology and Transfusion Medicine
Bonn, Germany

Johnny Mahlangu

Professor, University of the Witwatersrand and NHLS
Johannesburg, South Africa

Keiji Nogami

Professor, MD, Department of Pediatrics - Nara Medical University
Kashihara, Japan

Krishnan Viswanadhan

President & Chief Operating Officer, Be Biopharma
Cambridge, United States

Lindsey George

Assistant Professor, Perelman School of Medicine, University of Pennsylvania and Director of Clinical In Vivo Gene Therapy, Children’s Hospital
Philadelphia, United States

Lisa Wilcox

Global Medical Lead - Hemophilia, Pfizer
Greater Toronto Area, Canada

Louis Garrison

Professor, University of Washington
Washington, United States

Magdalena Lewandowska

Adult Hematologist-Oncologist, Indiana Hemophilia and Thrombosis Center (IHTC)
Indianapolis, United States

Margareth C. Ozelo

Professor, Hemocentro Unicamp
Sao Paulo, Brazil

Mark Skinner

President and CEO, Institute for Policy Advancement Ltd

Martynas Aizenas

Global Access Strategy Leader, Roche
Basel, Switzerland

Mayss Naccache

Head - Gene Therapy Program, WFH
Montreal, Canada

Meagan O'Brien

Clinical Medical Director Program Lead, Regeneron Pharmaceuticals, Inc.
United States

Miguel Escobar

Professor, University of Texas
Austin, United States

Mike Makris

Professor, University of Sheffield
United Kingdom

Nathan Connell

Assistant Professor of Medicine, Brigham and Women's Faulkner Hospital
Boston, United States

Pratima Chowdary

Consultant Haematologist, Royal Free Hospital
London, United Kingdom

Radoslaw Kaczmarek

Assistant Research Professor of Pediatrics Wells Center for Pediatric Research, Indiana University School of Medicine
Indianapolis, United States

Renchi Yang

Head of Thrombosis and Hemostasis Centre
Institute of Hematology and Blood Diseases Hospital
Tianjin, China

Salome Mekhuzla

Director, Global Development, WFH
Montreal, Canada

Samantha Gouw

Pediatric Hematologist, Amsterdam UMC
Amsterdam, Netherlands

Sophie Susen

Director of the Department of Haemostasis & Transfusion, CHRU Lille
Lille, France

Steve Lentz

Henry Hamilton Chair in Hematology, The University of Iowa Carver College of Medicine
Iowa City, United States

Steve Pipe

Professor Pediatric Hematology/Oncology, Michigan Medicine Hemophilia/Coagulation
Ann Arbor, United States

Thomas Sannié

Honorary President, Association Française des Hémophiles
France

Ulrike Reiss

Director, Pediatric Hemophilia Treatment Center - St. Jude Children’s Research Hospital.
United States

SPONSORS

For more information on sponsorship opportunities for the 13th Global Forum, please contact our Corporate Relations Manager at cpp@wfh.org.

The 13th edition of the WFH Global Forum is supported by funding from:

SILVER SPONSORS

COMMITTEE & SPEAKERS

pending

Assistant Professor

Thrombosis and Atherosclerosis Research Institute (TaARI) – McMaster University

Hamilton, Canada

Head of Thrombosis and Hemostasis Centre
Institute of Hematology and Blood Diseases Hospital
Tianjin, China

REGISTRATION INFORMATION

Note: the 13th WFH Global Forum is only offered in English.

The WFH Global Forum will take place in-person in Montreal, Canada. Registration will open in June. Please send an email to gf@wfh.org for group registrations of 10 participants or more.

Category Registration fee (in USD)
Industry $1,000.00
Delegate $765.00
PAMs (professions allied to medicines) $465.00
Government agency $250.00
NMO staff or volunteer $250.00
Young researcher/students $250.00
PWBD/family member $150.00
  • Access to all sessions
  • Electronic access to the final program
  • Daily buffet breakfast
  • Daily coffee breaks
  • Daily lunch
  • Certificate of attendance (by request)
  • Welcome reception

For any registration inquiries, please contact gf@wfh.org.

RELEVANT RESOURCES

Interested in catching up on the discussions from GPAS 2021 and 2022? View recordings of select sessions on the WFH eLearning platform.

VENUE

Nestled in the heart of beautiful Montreal, the Fairmont Queen Elizabeth hotel is an iconic landmark that has been welcoming guests for over six decades. The hotel includes various dining options, state-of-the-art facilities, a fitness center, and a spa.

The hotel booking page will be available until October 13, 2023. After October 13, 2023, hotel rooms are subject to availability and rates cannot be guaranteed. Please send an email to gf@wfh.org to check availability after October 13, 2023.

Nightly room rate: $279 USD (inclusive of all taxes and fees)

We look forward to welcoming you!

TRAVEL

We are delighted to announce that Air Canada, Air France, and KLM have partnered with the WFH to offer exclusive flight discount rates of up to 15% for attendees of the WFH Global Forum. Take advantage of these discounted flight options and be part of the conversation at the Global Forum!

Booking your discounted flight with Air Canada, Air France, and KLM to attend the Global Forum is easy:

  1. Register for the WFH Global Forum
  2. Follow the flight booking instructions received in your registration confirmation email
  3. Enter the discounted rates from the email when booking your flight to Montreal, Canada
  4. Enjoy your flight!
  • The discounted rates are applicable only for travel to Montreal for the Global Forum
  • Discounted seats are subject to availability, so we recommend booking early to secure your preferred flights
  • The discounts may vary based on the class of travel and availability

For more information, please contact gf@wfh.org.

FAQ

Please contact gpas@wfh.org for more information.

QWho would benefit from attending GPAS?
A
  • WFH NMO leaders and advocates
  • Healthcare professionals
  • National governments
  • Other organizations representing the interests of people with bleeding disorders
  • Regional and global government agencies (such as the WHO, etc.) and partner organizations
  • Industry representatives
  • Researchers and any individuals with interest in the field of bleeding disorders
QWill recordings be made available after the event?
AAll sessions will be made available on demand after the event.
QWill there be any live interpretation?
AThe event will feature live interpretation in Spanish, French, Arabic and Russian.
QWhen will I receive my login information to access the virtual event?
ALogin information will be sent to all registered attendees on July 4, 2023

EVENT NEWS

< PREV NEXT >
Members of the Ludhiana hemophilia treatment centre (HTC).

Integrating myofascial therapy and understanding life beyond the bleeds

Living with hemophilia involves more than managing bleeds. People with hemophilia (PWH), particularly in low-resource settings like India, face not only physical challenges such as joint pain and limited mobility but also social, emotional, and financial hardships. For caregivers, these burdens are equally significant. Recognizing the need for a more integrated approach to care, the hemophilia treatment centre (HTC) at Christian Medical College and Hospital in Ludhiana in India (HTC Ludhiana) has conducted a research initiative focusing on rehabilitation through physiotherapy while exploring the everyday experience of PWH and their families.

The GPAS 2025 full program is live: explore what’s coming this July!

The GPAS 2025 full program is live: explore what’s coming this July!

The WFH is pleased to announce that the full program for the Global Policy and Access Summit (GPAS) 2025 is now live! Join us virtually on July 10 to 11 for two days of impactful sessions and discussions focused on improving access to diagnosis, treatment, and care for people with bleeding disorders worldwide.

Register now for the WFH Global Policy and Access Summit

Register now for the WFH Global Policy and Access Summit

We are excited to announce that registration for the fourth WFH Global Policy and Access Summit (GPAS) is now open! This two-day virtual event will take place on July 10 to 11, 2025 and is a unique opportunity to be part of the conversation around strategies for sustaining and advancing bleeding disorders care in today’s fast-changing world.